IMARC Group has recently released a new research study titled “Mexico Cancer Biomarkers Market Size, Share, Trends and Forecast by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region, 2025-2033” which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

Market Overview

The Mexico cancer biomarkers market size reached USD 469.5 Million in 2024, with a forecast to reach USD 1,211.8 Million by 2033. The market is anticipated to grow at a CAGR of 11.11% during the forecast period 2025-2033. Growth is driven by rising cancer incidence, increased awareness and screening, adoption of precision medicine, advancements in biomarker-based diagnostics, and expanding healthcare infrastructure that supports early detection and targeted therapies.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Mexico Cancer Biomarkers Market Key Takeaways

• Current Market Size: USD 469.5 Million in 2024
• CAGR: 11.11% (2025-2033)
• Forecast Period: 2025-2033
• Regulatory clearance of broad-spectrum oncology assays detecting over 500 gene biomarkers, including NTRK and RET fusions, is expanding genetic testing access.
• The FDA approved Illumina’s TruSight Oncology Comprehensive (TSO Comp) test in August 2024, enhancing adoption of pan-cancer biomarker-driven diagnostics.
• Collaborations such as BD and Quest Diagnostics' July 2024 partnership to develop flow cytometry-based companion diagnostics aim to improve personalized cancer diagnostics.
• Market segmentation covers profiling technology, biomolecule, cancer type, application, end user, and region.
• Growing precision oncology efforts and regulatory-approved diagnostic kits in Mexico are expected to significantly drive market growth.

Sample Request Link: https://www.imarcgroup.com/mexico-cancer-biomarkers-market/requestsample

Mexico Cancer Biomarkers Market Growth Factors

The Mexico cancer biomarkers market is primarily propelled by rising cancer incidence and increasing awareness about early detection. Screening programs have expanded, supported by government and healthcare initiatives, leading to greater demand for biomarker-based diagnostics. The rise of precision medicine further encourages the use of biomarkers to enable targeted therapy approaches, improving patient outcomes. Adoption of biomarker testing facilitates more effective diagnosis and treatment personalization, fueling market expansion.

Technological advancements in biomarker-based diagnostics significantly impact market growth. For instance, the regulatory clearance of broad-spectrum oncology assays capable of detecting over 500 gene biomarkers, such as NTRK and RET fusions, represents a breakthrough in comprehensive genomic profiling. The FDA's approval of Illumina’s TruSight Oncology Comprehensive (TSO Comp) test in August 2024 serves as a landmark event indicating the integration of expansive molecular testing tools, which are especially relevant in precision oncology. These innovative diagnostics shorten the time to identify actionable mutations aiding targeted treatments.

Collaborative developments to strengthen precision diagnostics in oncology are another growth accelerator. The partnership between BD and Quest Diagnostics in July 2024 to co-develop flow cytometry-based companion diagnostics (CDx) is noteworthy. This initiative focuses on delivering end-to-end solutions from biomarker panel development to regulatory-approved diagnostic kits. With both companies active in Mexico, their collaboration aims to enhance personalized diagnostic tools’ accuracy and throughput. This trend aligns with increasing demand for high-quality diagnostic platforms, improving clinical decision-making and treatment effectiveness across healthcare settings.

Mexico Cancer Biomarkers Market Segmentation

The market segmentation is categorized as follows:

Breakup by Profiling Technology:

• Omics Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics

Each profiling technology segment provides a focused approach to detecting and analyzing cancer biomarkers, leveraging molecular, imaging, immunological, and chromosomal characterization techniques.

Breakup by Biomolecule:

• Genetic Biomarkers
• Protein Biomarkers
• Glyco-Biomarkers

These biomolecules represent the distinct classes of biological markers used for cancer detection, varying in molecular nature and diagnostic application.

Breakup by Cancer Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Others

Segmentation by cancer type reflects the targeted application of biomarker diagnostics across prevalent and other less common cancer forms.

Breakup by Application:

• Diagnostics
• Prognostics
• Risk Assessment
• Drug Discovery and Development
• Others

These application segments cover biomarker use in clinical diagnosis, disease progression prediction, assessment of cancer risk, pharmaceutical research, and additional uses.

Breakup by End User:

• Hospitals
• Academic and Research Institutions
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others

End user classification indicates the various healthcare and research facilities utilizing cancer biomarker diagnostics.

Breakup by Region:

• Northern Mexico
• Central Mexico
• Southern Mexico
• Others

Regional segmentation assists in understanding geographic distribution and dominance within Mexico’s cancer biomarker market.

Regional Insights

Northern Mexico, Central Mexico, Southern Mexico, and other regions are all analyzed.

Ask an Analyst: https://www.imarcgroup.com/request?type=report&id=33511&flag=C

Recent Developments & News

In March 2025, Mexico’s Longevity Medical Institute adopted OncoSeek, an AI-powered multi-cancer detection test developed by OncoInv. This blood-based test analyzes over 70 protein biomarkers to detect more than 12 cancer types. It was launched as part of a national screening program, mainly targeting adults over 50 years old. This initiative marks a significant advancement in Mexico's cancer diagnostics landscape and is expected to strengthen the cancer biomarkers market in the country.

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302